Home » Topics » BioWorld Science

BioWorld Science
RSS

EI-1071 to enter phase I testing next year

Nov. 25, 2019

Oyster Point Pharma reports topline phase I results with OC-01 nasal spray for dry eye

Nov. 25, 2019

Clinical data presented for AT-001 in patients with T2D-derived diabetic cardiomyopathy

Nov. 25, 2019

Neuraly studies NLY-01 in phase II for type 2 diabetes

Nov. 25, 2019

Johnson & Johnson identifies new anti-HBV compounds

Nov. 25, 2019

Medshine Discovery describes new HER2 inhibitors

Nov. 25, 2019

Shanghai Longwood Biopharmaceuticals patents HBV caspid assembly inhibitors

Nov. 25, 2019

New RIP-1 inhibitors identified at Rigel Pharmaceuticals

Nov. 25, 2019

Amgen discovers KRAS G12C inhibitors

Nov. 25, 2019

New pan alphav antagonist with excellent oral PK properties and bioavailability for IPF treatment

Nov. 25, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...